Neurotech International Ltd Gains FDA IND Clearance for NTI164 US Pathway
US FDA clears IND for Neurotech’s NTI164, unlocking a US clinical pathway
The US Food and Drug Administration (FDA) has cleared Neurotech International’s (ASX: NTI) Investigational New Drug (IND) application for its lead therapy NTI164, marking a major regulatory milestone for the clinical-stage biopharmaceutical company.
The clearance authorises Neurotech to commence its proposed clinical development program for NTI164 in the United States. It establishes a formal US clinical development pathway to support potential future FDA registration.
Crucially, the milestone underpins Neurotech’s global commercialisation strategy and opens the door to strategic partnering opportunities. The announcement was authorised for release by the Board on 14 July 2026.
When big ASX news breaks, our subscribers know first
What the IND clearance means for Neurotech
The IND submission included the Company’s chemistry, manufacturing and controls (CMC), non-clinical and clinical information supporting the proposed clinical and development program. According to the Company, the FDA has completed its review of this CMC, non-clinical and clinical data package.
Importantly, the clearance authorises, but does not obligate, Neurotech to proceed. Any US study would only advance should the Company elect to commence clinical development. The US program has not yet begun.
Key highlights from the announcement include:
-
FDA clears IND for NTI164
-
Authorises initiation of the US clinical development program
-
Establishes a formal US pathway toward potential future FDA registration
-
Designed to complement the Australian Phase 3 “Beyond Harmony” trial
-
Supports the global commercialisation strategy and strategic partnering opportunities
Anthony Filippis, CEO and Managing Director
“FDA clearance of our IND application is a major milestone for Neurotech and marks the formal establishment of our US clinical development pathway for NTI164.”
An integrated global registration strategy
Should the Company elect to proceed, the study conducted under the FDA-cleared IND would be a comprehensive population pharmacokinetic (PopPK) program. It has been strategically designed to complement the Australian Phase 3 “Beyond Harmony” trial.
The Australian Phase 3 trial is intended to generate pivotal efficacy and safety data for NTI164 in paediatric patients with ASD. The two programs are designed to play complementary roles. The Phase 3 trial would deliver pivotal efficacy and safety data, while the US PopPK study would generate pharmacokinetic data to support dose characterisation and product registration.
Separately, Neurotech continues to engage proactively with the Australian Therapeutic Goods Administration (TGA) to ensure alignment of its Australian and US regulatory strategies. The Company is using its interactions with both the FDA and TGA to progress the global development pathway and the potential use of clinical data across multiple regulatory jurisdictions.
| Program | Location | Type | Purpose |
|---|---|---|---|
| Beyond Harmony | Australia | Phase 3 | Pivotal efficacy & safety data |
| Proposed IND Program | US | PopPK | Dose characterisation & registration data |
| Regulatory engagement | AU + US | FDA & TGA | Cross-jurisdiction alignment |
Together, these workstreams are expected to generate an integrated efficacy, safety, pharmacokinetic and regulatory data package to support Neurotech’s global development, registration and commercialisation strategy for NTI164.
Understanding IND clearance and NTI164
For investors less familiar with the regulatory process, the clearance authorises Neurotech to commence its proposed clinical development program for NTI164 in the United States.
NTI164 itself is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. According to the Company, preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation and upstream biological mechanisms implicated in neurodevelopmental disorders.
Neurotech is a clinical-stage biopharmaceutical company focused predominantly on paediatric neurological disorders. It has completed trials across Autism Spectrum Disorder (ASD), PANDAS/PANS and Rett Syndrome, and has received human ethics committee clearance for a Phase III clinical study in ASD.
The investment case, a differentiated and well-protected asset
The IND clearance follows closely on the heels of Neurotech’s recently strengthened US intellectual property portfolio, which included Notices of Allowance for key US patent applications per the ASX announcement released on 2 July 2026.
The US patent allowance notices, covering neuroinflammation reduction and ASD treatment applications with protection expected to extend to 2042, were issued just two weeks before the IND clearance, reinforcing the paired IP and regulatory foundation Neurotech is assembling for the US market.
Taken together, the Company describes itself as continuing to build a differentiated and well-protected asset with increasing strategic value. These milestones support Neurotech as it continues discussions with potential strategic partners.
These milestones support the Company as it continues discussions with potential strategic partners as it advances its development, regulatory and commercialisation strategy.
The next major ASX story will hit our subscribers first
What comes next
Neurotech may elect to commence the US clinical development program under the cleared IND. No specific timelines, trial dates, patient numbers or cost figures were disclosed in the announcement.
The Australian Phase 3 “Beyond Harmony” trial continues, with results expected to form an important component of the global clinical evidence package. The Company will maintain ongoing engagement with both the FDA and TGA to progress the integrated global development pathway.
The strategic objective, as outlined by the Company, is to build a comprehensive and integrated efficacy, safety, pharmacokinetic and regulatory evidence package supporting global development, registration and commercialisation for NTI164.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to ensure the next major ASX healthcare announcement lands in your inbox the moment it breaks.